Sepsivac
Sepsivac ne wani labari miyagun ƙwayoyi ci gaba da Cadila Pharmaceuticals to bi da marasa lafiya na gram-korau sepsis marasa lafiya . A matsayin immunomodulatory, yana daidaita tsarin rigakafi na jiki kuma saboda haka yana rage yawan mace-mace a cikin marasa lafiya tare da gram korau sepsis. Sepsivac magani ne wanda CSIR da Cadila Pharmaceuticals suka haɓaka a ƙarƙashin Sabon Tsarin Jagorancin Fasaha na Indiya na Millennium (NMITLI).[1] A lokuta da yawa, Sepsivac ya tabbatar da ba da ingantaccen kulawa da sauƙi ga marasa lafiya na COVID.[2]
 Sepsivac |
|---|
Makanikai
A cikin marasa lafiya tare da sepsis, don mayar da martani ga kamuwa da cuta, yawancin cytokines pro-inflammatory da anti-inflammatory suna haifar da jiki. Duk da haka, wasu daga cikin cytokines kuma suna haifar da kumburi a cikin gabobin jiki, wanda zai iya zama cutarwa. Magungunan Immunomodulator irin su Sepsivac suna daidaita wannan kuma amsawar rigakafi.[3] Ana samun Sepsivac yana da aminci a cikin marasa lafiya waɗanda ba su da lahani na tsari. Ana iya amfani da shi tare da wasu jiyya don sarrafa majiyyaci a wuri mai mahimmanci.[4]
Sepsivac da kuma COVID-19
Masana kimiyya a CSIR sun sami kamance tsakanin halayen asibiti na marasa lafiya da ke fama da sepsis gram-negative da COVID-19 . A cikin haɗin gwiwa tare da Cadila Pharmaceuticals, masu binciken yanzu suna aiki kan ƙaddamar da bazuwar, makafi, gwajin gwaji na asibiti don kimanta ingancin Sepsivac don rage mace-mace a cikin marasa lafiya na COVID-19 masu tsananin rashin lafiya.[1] Maganin da aka sake amfani da shi zai haɓaka garkuwar jiki tare da iyakance yaduwar COVID-19 da haɓaka ƙimar murmurewa.[5] Za a gudanar da gwajin gwajin a asibitocin farko na kasa kamar PGIMER Chandigarh, AIIMS New Delhi da AIIMS, Bhopal.[6]
.png){kind=link}
